Johnson & Johnson $JNJ Stock: Mawer Investment Management Ltd. Decreases Stake

Mawer Investment Management Ltd. lessened its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 16.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 270,951 shares of the company’s stock after selling 51,526 shares during the quarter. Mawer Investment Management Ltd.’s holdings in Johnson & Johnson were worth $71,732,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Outlook Capital Management LLC acquired a new position in Johnson & Johnson during the 2nd quarter worth approximately $28,000. Navigoe LLC raised its holdings in shares of Johnson & Johnson by 60.4% in the third quarter. Navigoe LLC now owns 146 shares of the company’s stock valued at $38,000 after purchasing an additional 55 shares during the last quarter. Matrix Trust Co raised its holdings in shares of Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after purchasing an additional 54 shares during the last quarter. Montgomery Financial Services LLC bought a new stake in shares of Johnson & Johnson in the second quarter worth $43,000. Finally, Hanseatic Management Services Inc. bought a new stake in shares of Johnson & Johnson in the third quarter worth $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Latest Johnson & Johnson News

Investors following JNJ have been watching these news items:

Analysts Set New Price Targets

JNJ has been the subject of several recent research reports. Bank of America restated a “neutral” rating and set a $278.00 target price on shares of Johnson & Johnson in a report on Tuesday, September 29th. Wells Fargo & Company raised their target price on shares of Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a research report on Friday, October 16th. Argus set a $300.00 price target on shares of Johnson & Johnson in a research note on Wednesday, July 29th. Evercore set a $300.00 price target on shares of Johnson & Johnson in a research report on Tuesday, October 20th. Finally, Leerink Partners reduced their price objective on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating for the company in a research note on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $275.92.

View Our Latest Report on JNJ

Johnson & Johnson Stock Up 0.8%

Shares of Johnson & Johnson stock traded up $2.26 on Friday, reaching $285.78. 6,279,519 shares of the company were exchanged, compared to its average volume of 7,472,752. Johnson & Johnson has a one year low of $193.55 and a one year high of $288.11. The company has a market capitalization of $687.95 billion, a price-to-earnings ratio of 43.30, a PEG ratio of 2.80 and a beta of 0.22. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The company has a 50-day moving average of $266.97 and a 200 day moving average of $249.85.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same quarter in the prior year, the firm posted $2.80 EPS. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 81.21%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 15,000 shares of the business’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. The trade was a 7.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 61,669 shares of company stock worth $16,898,386 over the last quarter. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.